October 9, 2006 -- New River Pharmaceuticals passed a significant corporate milestone late on Friday when it received an approvable letter from the FDA for NRP104, an abuse-resistant therapy for ADHD. New River says the FDA is waiting only for the Drug Enforcement Agency to issue a scheduling ruling on the drug – it does not want New River to conduct additional clinical trials on NRP104. New River jumped 69% higher, because the approval means a lot to the company. We look at the details...
